Tanshinol Alleviates Osteoporosis and Myopathy in Glucocorticoid-Treated Rats

Guanghua Chen; Xinle Zhang; Han Lin; Guizhi Huang; Yahui Chen; Liao Cui

doi:10.1055/s-0043-108761

Planta Medica, Table of Contents

Planta Med 2017; 83(16): 1264-1273
DOI: 10.1055/s-0043-108761

Biological and Pharmacological Activity

Original Papers

Georg Thieme Verlag KG Stuttgart · New York

Tanshinol Alleviates Osteoporosis and Myopathy in Glucocorticoid-Treated Rats

Guanghua Chen^*

¹Department of Orthopedics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China

,

Xinle Zhang^*

²Department of Pharmacology, School of Pharmacy, Guangdong Medical University, Zhanjiang, Guangdong, China

,

Han Lin^*

³Department of Orthopedics, Affiliated Hospital of Guizhou Medical University, Guian, Guizhou, China

,

Guizhi Huang^*

¹Department of Orthopedics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China

,

Yahui Chen

²Department of Pharmacology, School of Pharmacy, Guangdong Medical University, Zhanjiang, Guangdong, China

,

Liao Cui

²Department of Pharmacology, School of Pharmacy, Guangdong Medical University, Zhanjiang, Guangdong, China

⁴Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang, Guangdong, China

› Author Affiliations

Abstract

Tanshinol is a major water-soluble active component of Salvia miltiorrhiza. In this study, we aimed to investigate whether tanshinol has potential therapeutic effects against glucocorticoid-induced osteoporosis and glucocorticoid-induced myopathy. Ninety-six female Sprague-Dawley rats were randomly assigned to five groups: a control group, a model group, and three model groups treated with 25 or 50 mg/kg of tanshinol, or calcitriol. All model groups received prednisone acetate for 90 days to induce glucocorticoid-induced osteoporosis. Afterwards, all animals underwent a surgical procedure to induce bone defects at the right proximal tibia. Prednisone treatment was stopped after surgery, but tanshinol or calcitriol treatment was continued to the endpoint. At the experimental endpoint, compared to the model group, 25 mg/kg tanshinol could significantly reverse glucocorticoid-induced loss of bone mineral density by 12.5 %, while enhancing mechanical bone strength, causing a significant 11 % increase in trabecular number, and reducing trabecular separation by 28 %. In addition, tanshinol improved the bone microarchitecture and prevented glucocorticoid-induced bone loss by promoting bone formation and inhibiting bone resorption. Moreover, results of bone defect repair and muscle weight measurements revealed that tanshinol accelerated the bone fracture healing process and attenuated muscle atrophy caused by glucocorticoid. Furthermore, qRT-PCR analysis showed a 1-fold upregulation in mRNA levels of transforming growth factor beta and roughly 6-fold increases in vascular endothelial growth factor mRNA expression in calluses from the tanshinol groups. Tanshinol also preserved muscular ubiquitin mRNA levels from glucocorticoid-induced elevation. These findings demonstrate the potential benefits of tanshinol against glucocorticoid-induced osteoporosis and glucocorticoid-induced myopathy, which warrants further investigation in future studies.

Key words

glucocorticoid - osteoporosis - fracture - myopathy - tanshinol - Salvia miltiorrhiza - Lamiaceae - bone histomorphometry

Full Text

References

References
1 Müller R, Kampschulte M, Khassawna TE, Schlewitz G, Hürter B, Böcker W, Bobeth M, Langheinrich AC, Heiss C, Deutsch A, Cuniberti G. Change of mechanical vertebrae properties due to progressive osteoporosis: combined biomechanical and finite-element analysis within a rat model. Med Biol Eng Comput 2014; 52: 405-414
2 Siu WS, Ko CH, Lam KW, Wat E, Shum WT, Lau CB, Ko KM, Hung LK, Lau DT, Leung PC. Evaluation of a topical herbal agent for the promotion of bone healing. Evid Based Complement Alternat Med 2015; 2015: 905270
3 Bindl R, Oheim R, Pogoda P, Beil FT, Gruchenberg K, Reitmaier S, Wehner T, Calcia E, Radermacher P, Claes L, Amling M, Ignatius A. Metaphyseal fracture healing in a sheep model of low turnover osteoporosis induced by hypothalamic-pituitary disconnection (HPD). J Orthop Res 2013; 31: 1851-1857
4 Lim SY, Bolster MB. Current approaches to osteoporosis treatment. Curr Opin Rheumatol 2015; 27: 216-224
5 Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open 2015; 1: e000014
6 Scillitani A, Mazziotti G, Di Somma C, Moretti S, Stigliano A, Pivonello R, Giustina A, Colao A, Group ABC. Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. Osteoporos Int 2014; 25: 441-446
7 Tu J, Henneicke H, Zhang Y, Stoner S, Cheng TL, Schindeler A, Chen D, Tuckermann J, Cooper MS, Seibel MJ, Zhou H. Disruption of glucocorticoid signaling in chondrocytes delays metaphyseal fracture healing but does not affect normal cartilage and bone development. Bone 2014; 69: 12-22
8 Peppone LJ, Hebl S, Purnell JQ, Reid ME, Rosier RN, Mustian KM, Palesh OG, Huston AJ, Ling MN, Morrow GR. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos Int 2010; 21: 1133-1149
9 Kenanidis E, Potoupnis ME, Kakoulidis P, Leonidou A, Sakellariou GT, Sayegh FE, Tsiridis E. Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk. Expert Opin Drug Saf 2015; 14: 1035-1053
10 Rossini M, Orsolini G, Viapiana O, Adami S, Gatti D. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. Endocrine 2015; 49: 620-627
11 Doga M, Mazziotti G, Bonadonna S, Patelli I, Bilezikian JP, Canalis E, Giustina A. Prevention and treatment of glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008; 31: 53-58
12 Li C, Li Q, Liu R, Niu Y, Pan Y, Zhai Y, Mei Q. Medicinal herbs in the prevention and treatment of osteoporosis. Am J Chin Med 2014; 42: 1-22
13 Cui Y, Bhandary B, Marahatta A, Lee GH, Li B, Kim DS, Chae SW, Kim HR, Chae HJ. Characterization of Salvia miltiorrhiza ethanol extract as an anti-osteoporotic agent. BMC Complement Altern Med 2011; 11: 120
14 Cui L, Li T, Liu Y, Zhou L, Li P, Xu B, Huang L, Chen Y, Liu Y, Tian X, Jee WS, Wu T. Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis. PLoS One 2012; 7: e34647
15 Cui L, Liu YY, Wu T, Ai CM, Chen HQ. Osteogenic effects of D+beta-3,4-dihydroxyphenyl lactic acid (salvianic acid A, SAA) on osteoblasts and bone marrow stromal cells of intact and prednisone-treated rats. Acta Pharmacol Sin 2009; 30: 321-332
16 Yang Y, Su Y, Wang D, Chen Y, Wu T, Li G, Sun X, Cui L. Tanshinol attenuates the deleterious effects of oxidative stress on osteoblastic differentiation via Wnt/FoxO3a signaling. Oxid Med Cell Longev 2013; 2013: 351895
17 Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000; 11: 192-202
18 Lewiecki EM, Lane NE. Common mistakes in the clinical use of bone mineral density testing. Nat Clin Pract Rheumatol 2008; 4: 667-674
19 Weng MY, Lane NE. Medication-induced osteoporosis. Curr Osteoporos Rep 2007; 5: 139-145
20 Leib ES, Winzenrieth R. Bone status in glucocorticoid-treated men and women. Osteoporos Int 2016; 27: 39-48
21 Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012; 41: 595-611
22 Delany AM, Pereira RM, Pereira RC, Canalis E. The cellular and molecular basis of glucocorticoid actions in bone. Front Horm Res 2002; 30: 2-12
23 Oktas B, Orhan Z, Erbil B, Degirmenci E, Ustundag N. Effect of extracorporeal shock wave therapy on fracture healing in rat femural fractures with intact and excised periosteum. Eklem Hastalik Cerrahisi 2014; 25: 158-162
24 Tajima S, Tobita M, Orbay H, Hyakusoku H, Mizuno H. Direct and indirect effects of a combination of adipose-derived stem cells and platelet-rich plasma on bone regeneration. Tissue Eng Part A 2015; 21: 895-905
25 Krishnan L, Priddy LB, Esancy C, Li MT, Stevens HY, Jiang X, Tran L, Rowe DW, Guldberg RE. Hydrogel-based delivery of rhBMP-2 improves healing of large bone defects compared with autograft. Clin Orthop Relat Res 2015; 473: 2885-2897
26 Weigand A, Beier JP, Hess A, Gerber T, Arkudas A, Horch RE, Boos AM. Acceleration of vascularized bone tissue-engineered constructs in a large animal model combining intrinsic and extrinsic vascularization. Tissue Eng Part A 2015; 21: 1680-1694
27 Mazziotti G, Giustina A, Canalis E, Bilezikian JP. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metabol 2007; 51: 1404-1412
28 Migliaccio S, Brama M, Malavolta N. Management of glucocorticoids-induced osteoporosis: role of teriparatide. Ther Clin Risk Manag 2009; 5: 305-310
29 Zelzer E, McLean W, Ng YS, Fukai N, Reginato AM, Lovejoy S, DʼAmore PA, Olsen BR. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002; 129: 1893-1904
30 Street J, Bao M, deGuzman L, Bunting S, Peale jr. FV, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 2002; 99: 9656-9661
31 Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, Huard J. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 2002; 110: 751-759
32 Shi CG, Yang YS, Li H, Zhang Y, Wang N, Wang SM, Wang JD, Zhang SC. Tanshinol protects hippocampus and attenuates vascular dementia development. J Asian Nat Prod Res 2014; 16: 667-676
33 Schakman O, Kalista S, Barbe C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013; 45: 2163-2172
34 SantʼAnna EF, Leven RM, Virdi AS, Sumner DR. Effect of low intensity pulsed ultrasound and BMP-2 on rat bone marrow stromal cell gene expression. J Orthop Res 2005; 23: 646-652
35 Zhu LJ, Altmann SW. mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. Anal Biochem 2005; 345: 102-109

Supplementary Material

Supporting Information